Genetic predisposition to adverse consequences of anti–cholinesterases in ‘atypical’ BCHE carriers

Nature Medicine

Volumn 1, Issue 10, 1995, Pages 1082-1085

  Loewenstein Lichtenstein, Yael ^a,d   Schwarz, Mikael ^a   Glick, David ^a   Nørgaard Pedersen, Bent ^b   Zakut, Haim ^c   Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b STATENS SERUM INSTITUT   (Denmark)

^c WOLFSON MEDICAL CENTER   (Israel)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HEPTYLPHYSOSTIGMINE; NERVE GAS; PHYSOSTIGMINE; PYRIDOSTIGMINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; ETIOLOGY; FATIGUE; GAS POISONING; GENETIC PREDISPOSITION; HUMAN; INSOMNIA; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT REDUCTION;

ACETYLCHOLINESTERASE; BINDING SITES; BUTYRYLCHOLINESTERASE; BUTYRYLTHIOCHOLINE; CARBAMATES; CASE REPORT; CHOLINESTERASE INHIBITORS; HOMOZYGOTE; HUMAN; MALE; PYRIDOSTIGMINE BROMIDE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; TACRINE;

EID: 0028843893     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1095-1082     Document Type: Article

References (25)

1. Schwarz, M., Gltck, D., Loewenstein, Y. & Soreq, H. Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol. Ther. (in the press).
2. La Du, B.N. et al. Phenotypic and molecular biological analysis of human bu-tyrylcholinesterase variants. Clin. Biochem. 23, 423-431 (1990).
3. Keeler, J.R., Hurst, C.G. & Dunn, M.A. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA 266, 693-695 (1991).
4. Winker, M.A. Tacrine for Alzheimer’s disease; which patient, what dose? JAMA 271, 1023-1024 (1994).
5. Sharabi, Y. et al. Survey of symptoms following intake of pyridostigmine during the Persian Gulf War. Isr. J. med. Sci. 27, 656-658 (1991).
6. Neville, L.F. et al. Intramolecular relationships in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BCHE. EMBO J. 11, 1641-1649 (1992).
7. McGuire, M.C. et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc. natn. Acad. Sci. U.S.A. 86, 953-957 (1989).
8. Kalow, W. & Davis, R.O. The activity of various esterase inhibitors towards atypical human serum cholinesterase. Biochem. Pharmacol. 1, 183-192 (1958).
9. Lockridge, O. Genetic variants of serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol. Ther. 47, 35-60 (1990).
10. Ehrlich, G. et al. Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes of Israeli Jews from Transcaucasian Georgia and from Europe. Genomics 22, 288-295 (1994).
11. Soreq, H. & Zakut, H. Human Cholinesterases and Anticholinesterases (Academic Press, San Diego, California, 1993).
12. Schwarz, M. et al. Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants. Molec. Brain Res. 31, 101-110 (1995).
13. Seidman, S. et al. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 3’-terminal exons. Molec. cell. Biol. 15, 2993-3002 (1995).
14. Chatonnet, A. & Lockridge, O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 260, 625-634 (1989).
15. Giacobini, E. The second generation of cholinesterase inhibitors: Pharmacological aspects, in Cholinergic Basis for Alzheimer Therapy (eds Becker, R. & Giacobini, E.) 247-262 (Birkhauser, Boston, 1991).
16. Iversen, L.L. Approaches to cholinergic therapy in Alzheimer’s disease. Prog. Brain. Res. 98, 423-426 (1993).
17. Enz, A., Amstutz, R., Boddeke, H., Gmelin, G. & Malonowski, J. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer’s disease. Prog. Brain Res. 98, 431-437 (1993).
18. Harel, M. et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. natn. Acad. Sci. U.S.A. 90, 9031-9035 (1993).
19. Harel, M. et al. Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis. Proc. natn. Acad. Sci. U.SA. 89, 10827-10831 (1992).
20. Valentino, R.J., Lockridge, O., Eckerson, H.W. & La Du, B.N. Prediction of drug sensitivity in Individuals with atypical serum cholinesterase based on in vitro biochemical studies. Biochem. Pharmacol. 30, 1643-1649 (1981).
21. Gavageran, H. NIH panel rejects Persian Gulf syndrome. Nature 369, 8 (1994).
22. Ott, P. Lustig, A., Brodbeck, U. & Rosenbusch, J.P. Acetylcholinesterase from human erythrocyte membranes: Dimers as functional units. FEBS Lett. 138, 187-189 (1982).
23. Johansson, I.M. & Nordberg, A. Pharmacokinetic studies of cholinesterase inhibitors. Acta neurol. scand. Suppl. 149, 22-25 (1993).
24. Berman, H.A. & Leonard, K. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase. Molec. Pharmacol. 41, 412-418 (1992).
25. May, D.G. Genetic differences in drug disposition. J. clin. Pharmacol. 34, 881-897 (1994).